Adrenal and ovarian steroid hormone responses to gonadotropin-releasing hormone agonist treatment in polycystic ovary syndrome

Frank Gonzalez, Denise A. Hatala, Leon Speroff

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

It has been postulated that in polycystic ovary syndrome ovarian steroids can influence adrenal steroidogenesis. To test this hypothesis, basal and dexamethasone-suppressed-corticotropin-stimulated steroid hormone responses were compared among three groups of women before, during, and after gonadotropin-releasing hormone agonist treatment for 3 months. The groups were characterized as follows: (1) women with polycystic ovary syndrome with high dehydroepiandrosterone sulfate levels (>400 μg/dl), (2) women with polycystic ovary syndrome with normal dehydroepiandrosterone sulfate levels (

Original languageEnglish (US)
Pages (from-to)535-545
Number of pages11
JournalAmerican Journal of Obstetrics and Gynecology
Volume165
Issue number3
DOIs
StatePublished - 1991
Externally publishedYes

Fingerprint

Polycystic Ovary Syndrome
Gonadotropin-Releasing Hormone
Dehydroepiandrosterone Sulfate
Steroids
Hormones
Adrenocorticotropic Hormone
Dexamethasone
Therapeutics

Keywords

  • 3β-hydroxysteroid dehydrogenase deficiency
  • dehydroepiandrosterone sulfate
  • gonadotropin-releasing hormone agonist
  • Polycystic ovary syndrome

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

Adrenal and ovarian steroid hormone responses to gonadotropin-releasing hormone agonist treatment in polycystic ovary syndrome. / Gonzalez, Frank; Hatala, Denise A.; Speroff, Leon.

In: American Journal of Obstetrics and Gynecology, Vol. 165, No. 3, 1991, p. 535-545.

Research output: Contribution to journalArticle

@article{c372676a0ff94bdcb7b196a0cbbcf6f1,
title = "Adrenal and ovarian steroid hormone responses to gonadotropin-releasing hormone agonist treatment in polycystic ovary syndrome",
abstract = "It has been postulated that in polycystic ovary syndrome ovarian steroids can influence adrenal steroidogenesis. To test this hypothesis, basal and dexamethasone-suppressed-corticotropin-stimulated steroid hormone responses were compared among three groups of women before, during, and after gonadotropin-releasing hormone agonist treatment for 3 months. The groups were characterized as follows: (1) women with polycystic ovary syndrome with high dehydroepiandrosterone sulfate levels (>400 μg/dl), (2) women with polycystic ovary syndrome with normal dehydroepiandrosterone sulfate levels (",
keywords = "3β-hydroxysteroid dehydrogenase deficiency, dehydroepiandrosterone sulfate, gonadotropin-releasing hormone agonist, Polycystic ovary syndrome",
author = "Frank Gonzalez and Hatala, {Denise A.} and Leon Speroff",
year = "1991",
doi = "10.1016/0002-9378(91)90280-5",
language = "English (US)",
volume = "165",
pages = "535--545",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Adrenal and ovarian steroid hormone responses to gonadotropin-releasing hormone agonist treatment in polycystic ovary syndrome

AU - Gonzalez, Frank

AU - Hatala, Denise A.

AU - Speroff, Leon

PY - 1991

Y1 - 1991

N2 - It has been postulated that in polycystic ovary syndrome ovarian steroids can influence adrenal steroidogenesis. To test this hypothesis, basal and dexamethasone-suppressed-corticotropin-stimulated steroid hormone responses were compared among three groups of women before, during, and after gonadotropin-releasing hormone agonist treatment for 3 months. The groups were characterized as follows: (1) women with polycystic ovary syndrome with high dehydroepiandrosterone sulfate levels (>400 μg/dl), (2) women with polycystic ovary syndrome with normal dehydroepiandrosterone sulfate levels (

AB - It has been postulated that in polycystic ovary syndrome ovarian steroids can influence adrenal steroidogenesis. To test this hypothesis, basal and dexamethasone-suppressed-corticotropin-stimulated steroid hormone responses were compared among three groups of women before, during, and after gonadotropin-releasing hormone agonist treatment for 3 months. The groups were characterized as follows: (1) women with polycystic ovary syndrome with high dehydroepiandrosterone sulfate levels (>400 μg/dl), (2) women with polycystic ovary syndrome with normal dehydroepiandrosterone sulfate levels (

KW - 3β-hydroxysteroid dehydrogenase deficiency

KW - dehydroepiandrosterone sulfate

KW - gonadotropin-releasing hormone agonist

KW - Polycystic ovary syndrome

UR - http://www.scopus.com/inward/record.url?scp=0025863589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025863589&partnerID=8YFLogxK

U2 - 10.1016/0002-9378(91)90280-5

DO - 10.1016/0002-9378(91)90280-5

M3 - Article

C2 - 1832519

AN - SCOPUS:0025863589

VL - 165

SP - 535

EP - 545

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 3

ER -